TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hypertension diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptance of caraway-flavoured purée
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bone mineral density (vBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone geometry (cortical thickness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone strength (axial rigidity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symptomatic relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in healthcare resource use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: upgrading rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ≥25% reduction in ESS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epithelialization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of TGF beta1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite disease progression outcome (death or becoming ART eligible)
Endpoint domain: Mortality/survival
Primary endpoint: Plasma cTnI level at T(4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ICU staying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracheal time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with pain control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in C-reactive protein from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum triglyceride (TG) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: remnant‐like particle (RLP)‐TG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: apolipoprotein B‐48 (apoB48) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of time in target oxygen saturation range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of androstenedione, free testosterone, estradiol and DHT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum HDL-C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 3-year event-free survival (EFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: PEF% p
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Satisfactory mask induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative analgesia requirement
Endpoint domain: Adverse events/effects
Primary endpoint: Number of treated patients with antiplatelet drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricle basal dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade 3/4 toxic effects
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative success rate (CSR)
Endpoint domain: Mortality/survival
Primary endpoint: Ten-year implant cumulative survival rate (CSR)
Endpoint domain: Mortality/survival
Primary endpoint: Average 10-year bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum EE2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the curve (AUC) for EE2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum triglycerides concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in body mass index z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronicity rate
Endpoint domain: Mortality/survival
Primary endpoint: lower-leg volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nifedipine-induced lower-leg edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of growth of posttraumatic hemorrhagic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sex-related knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sex-related attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visualization and transparency during surgical stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capsular bag maintenance during intraocular lens implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of viscoelastic aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in total score on the Young Mania Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment outcome expectancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological failure risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: net bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in motion function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients examined and informed
Endpoint domain: Delivery of care
Primary endpoint: Proportion of patients with complaints about health care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean reduction in SSRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total effectiveness rate (TER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lapse risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transition from lapse to relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure or improvement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque (18)FDG uptakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days with heavy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative number of drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved performance on the Verbal Word Learning Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improved performance on Verbal Fluency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improved performance on Similarities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: maximal muscle performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores upon arrival to the recovery unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores at 1 hour while resting in bed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores while sitting at arrival in PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary hemostasis achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRSOM-31 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal cross-sectional area of the nasal cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination half-life (t(1/2)) of halofantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of N-desbutylhalofantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of N-desbutylhalofantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core temperature after 2 hours of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total distance moved by the canine center
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total distance moved by the canine apex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain experienced following the MOP procedure
Endpoint domain: Adverse events/effects
Primary endpoint: anti-FXa Cmax24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-FXa AUC(0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detectable anti-FXa concentration >0.1 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sputum weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatal and non-fatal myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: any diabetes-related endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Oral stereognostic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resume normal activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to last dose of pain medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of no longer needing pain medications at 3 days
Endpoint domain: Adverse events/effects
Primary endpoint: mean decline in GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: risk of clinical end points
Endpoint domain: Adverse events/effects
Primary endpoint: proteinuria levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ulcer healing rates at four weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer recurrence rates after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced alcohol craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (Shaw score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean percent stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VAS of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS of leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mouth dryness
Endpoint domain: Adverse events/effects
Primary endpoint: Target lesion size change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fentany dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awaking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First time insertion success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time taken to achieve airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Oropharyngeal leak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Best corrected visual acuity of 6/18 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: palpitations
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial β‐hydroxybutyrate incremental AUC (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LF reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: spinal bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of new vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Evaluation of palliative care quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hematoma evacuation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average GCS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength improvement value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Katz-ADL index score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lawton IADL scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DHA percentage in plasma and erythrocyte membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nervonic acid ratio in plasma and erythrocyte lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Latency in lower visual angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in dental hypersensitivity (DH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve (AUC) of tomopenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total clearance of tomopenem
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Misalignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of artifacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ovulation enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: insulin sensitivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: decrease in hyperandrogenemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: No episodes of drug‐induced hypomania or rapid cycling
Endpoint domain: Adverse events/effects
Primary endpoint: Improved or prolonged high quality of life for a minimum period of 4 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality-adjusted survival time
Endpoint domain: Mortality/survival
Primary endpoint: Number of shock waves administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fentanyl requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: choice stepping reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical component of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Aortic root parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Repair strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HDLC cholesterol increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean sitting diastolic blood pressure (SiDBP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of response (SiDBP <= 90 mm Hg or decrease from baseline of >= 10 mm Hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum HCV RNA level before therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPC mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cumulative risk of non-AIDS death
Endpoint domain: Mortality/survival
Primary endpoint: Serum HDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Triglyceride (TG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfactory glycemic control (HbA1 less than 50 mmol hydroxymethylfurfural/mol Hb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients' satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Handgrip strength (HGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Vitality component of Quality of Life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 5-min bleeding mass reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of facial nerve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non-inferior antiviral efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TC:HDL-c ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lymphatic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Good intubation conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased susceptibility values in the substantia nigra pars compacta (SNc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Shoulder abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total pregnancy rates
Endpoint domain: Life impact
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Per cycle pregnancy rates
Endpoint domain: Life impact
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction in percentage of calories consumed as fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in servings of fruit and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effect on fiber consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: more sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: less quiet waking states
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in PWVart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in central systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of FEV1 decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Platelets activation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Invasive ability of lung cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Luminous transmittance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choice of infant sleep position
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amount of smear layer removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year caries increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCLSS performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient discomfort reduction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in TDM-related workload
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sedation onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rates against H. pylori infection
Endpoint domain: Mortality/survival